EU calls for a return to full dosing of Genzyme's Fabrazyme

10/24/2010 | Reuters

The European Medicines Agency has recommended that doctors resume prescribing the full dose of Genzyme's Fabry disease drug Fabrazyme after the agency found a steady increase in adverse events among patients receiving a lower dose. Dosing of the treatment was reduced last year because of a supply shortage prompted by issues at Genzyme's manufacturing facility.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA